FDA Clearance Tracker · K243866
InVision Precision Cardiac Amyloid
Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this decision)Source: openFDAMethods & limitations
Decided
May 21, 2025
Substantially Equivalent
Time to decision
155 days
Received Dec 17, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K243866
- Device name
- InVision Precision Cardiac Amyloid
- Applicant location
- Los Angeles, CA
- Received
- Dec 17, 2024
- Decided
- May 21, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.2200
- Specialty
- Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SDJ. The earliest in FDA's data is K240860, decided Nov 15, 2024.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for K243866
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for InVision Medical Technology Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K232331 · Decided Apr 25, 2024 · 265 days after receipt
Device type: Automated Radiological Image Processing Software (QIH) · Radiology & Imaging
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.